drugset / Trial / NCT02264080

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers

NCT02264080

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess the pharmacokinetics and safety of WAL2014 capsules administered orally as a multiple dose to healthy adult male volunteers in double blind manner.

Timeline

Start
1999-03
Primary completion
1999-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Talsaclidine Small molecule Oral

Indications

No indication recorded.